Pfizer-backed analysis finds dearth of patient-reported outcomes in trials

An analysis of online data found that only 7.4% of 650 clinical trials for diabetes treatments included patient-reported outcomes, which are supposed to shed light on patients' experiences on the meds. The analytics group Context Matters and drug giant Pfizer ($PFE) partnered on the study, which analyzed data from the NIH's database. The findings were reported today at the 18th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference in New Orleans. Report